Despite the Federal Reserve's tapering, U.S. interest rates have followed the downward trajectory of eurozone rates in 2014, says Morningstar's Bob Johnson.
Vanguard Market Neutral has more than low costs going for it.
Morningstar's Christine Benz highlights some of her favorite ETFs and low-minimum-investment funds for new investors.
Recent clinical success in cystic fibrosis positions Vertex as a dominant player in this attractive rare-disease market.
Having one of the world's longest partnerships between countries dissolve could have large implications for the eurozone and beyond, says Newton Global Strategist Peter Hensman.
With solid growth prospects and dividend yields above 4%, income investors would be wise to consider high-quality utilities such as Southern Company, Duke, and Public Service Enterprise Group.
Ivy High Income's recent manager turnover and Templeton Developing Markets' long-deteriorating performance have led to downgrades, says Morningstar's Russ Kinnel.
The Fed's latest U.S. consumer finance report showed decent income growth overall--but not across the board.
Apple's event this week burnished more than its own reputation. Plus, Lululemon sprints ahead, but what about the long run?
The U.K. will remain a good hunting ground for dividend-paying stocks even if Scotland decides to become independent, says Morningstar's Josh Peters.